scholarly journals Potency, efficacy, and selectivity of GR64349 at human recombinant neurokinin NK2 and NK1 receptors

2019 ◽  
Vol 711 ◽  
pp. 134456
Author(s):  
Elisabetta Perdona ◽  
Palmina Cavallini ◽  
Anna Sava ◽  
Cristiana Griffante ◽  
Daniel J. Ricca ◽  
...  
Keyword(s):  
1994 ◽  
Vol 64 ◽  
pp. 275
Author(s):  
Mamoru Kanda ◽  
Kazuyoshi Kurahashi ◽  
Hiroaki Shirahase ◽  
Hachiro Usui ◽  
Shohei Nakamura ◽  
...  
Keyword(s):  

1993 ◽  
Vol 18 (3) ◽  
pp. 245-248 ◽  
Author(s):  
F.-Y. Zhao ◽  
K. Saito ◽  
S. Konishi ◽  
J.-Z. Guo ◽  
T. Murakoshi ◽  
...  

1998 ◽  
Vol 336 (2) ◽  
pp. 419-427 ◽  
Author(s):  
Omar M. A. EL-AGNAF ◽  
G. Brent IRVINE ◽  
Geraldine FITZPATRICK ◽  
W. Kenneth GLASS ◽  
David J. S. GUTHRIE

In an attempt to answer the question of whether or not the so-called tachykinin-like region of the Alzheimer β-amyloid protein [Aβ(25–35)] can act as a tachykinin, the sequences Aβ(25–35), Aβ(25–35)amide and their norleucine-35 and phenylalanine-31 analogues were synthesized. These peptides were examined with ligand binding studies, electron microscopy, CD and NMR. In all cases some differences were found between the Aβ(25–35) analogue and the corresponding Phe31 peptide. In addition, in ligand displacement studies on tachykinin NK1 receptors, only the Phe31 analogue showed activity comparable to that of genuine tachykinins. We conclude that peptides based on Aβ(25–35) but with a Phe residue at position 31 do display properties typical of a tachykinin, but that peptides with Ile at this position do not.


Peptides ◽  
1998 ◽  
Vol 19 (8) ◽  
pp. 1349-1357 ◽  
Author(s):  
Shigetomo Fukuhara ◽  
Midori Shimizu ◽  
Hironori Matsushima ◽  
Hidehito Mukai ◽  
Eisuke Munekata

Sign in / Sign up

Export Citation Format

Share Document